

## Multitarget Therapeutic Leads for Alzheimer's Disease: Quinolizidinyl Derivatives of Bi- and Tri-cyclic Systems as Dual Inhibitors of Cholinesterases and A $\beta$ Aggregation

M. Tonelli<sup>a,\*</sup>, M. Catto<sup>b,\*</sup>, B. Tasso<sup>a</sup>, F. Novelli<sup>a</sup>, C. Canu<sup>a</sup>, G. Iusco<sup>a</sup>, L. Pisani<sup>b</sup>, A. De Stradis<sup>c</sup>, A. Sparatore<sup>d</sup>, V. Boido<sup>a</sup>, A. Carotti<sup>b</sup>, F. Sparatore<sup>a</sup>

<sup>a</sup>Dipartimento di Farmacia, Università degli Studi di Genova, V.le Benedetto XV, 3, I-16132 Genova, Italy

<sup>b</sup>Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari "Aldo Moro", V. Orabona 4, I-70125 Bari, Italy

<sup>c</sup>Istituto di Virologia Vegetale del CNR, Università degli Studi di Bari "Aldo Moro", Via Amendola 165/A, I-70126 Bari (Italy).

<sup>d</sup>Dipartimento di Scienze Farmaceutiche "P. Pratesi", Università degli Studi di Milano, V. Mangiagalli 25, I-20133 Milano, Italy

-----  
\*Corresponding authors: Tel.: +390103538867; fax: +390103538399; e-mail: [michele.tonelli@unige.it](mailto:michele.tonelli@unige.it) (M. Tonelli); Tel.: +390805442803; fax: +390805442230; e-mail: [marco.catto@uniba.it](mailto:marco.catto@uniba.it) (M. Catto)

### Abstract

Based on the models of compounds capable of maintaining or restoring cell protein homeostasis and of inhibiting A $\beta$  oligomerization, 37 thioxanthen-9-one, xanthen-9-one, naphtho- and anthraquinone derivatives were tested for the direct inhibition of A $\beta$ (1–40) aggregation and for the inhibition of eeAChE and hsBChE. These compounds are characterized by basic side chains, mainly quinolizidinylalkyl moieties, that have been recently shown to produce potent ChEs inhibitors when linked to various bi- and tri-cyclic (hetero)aromatic systems. With very few exceptions, these compounds displayed inhibitory activity on both AChE and BChE and on the spontaneous aggregation of  $\beta$ -amyloid. In most cases IC<sub>50</sub> values were in the low micromolar and sub-micromolar range, but single compounds even reached nanomolar potency. The time course of amyloid aggregation in the presence of **2** (the most active compound with IC<sub>50</sub> = 0.84  $\mu$ M) revealed that these compounds may act as destabilizers of mature fibrils rather than mere inhibitors of fibrillization. Many compounds inhibited one or both ChEs and A $\beta$  aggregation with similar potency, a fundamental requisite for the possible development of therapeutics exhibiting a multitarget mechanism of action.

**Keywords:** Cholinesterase inhibitors;  $\beta$ -amyloid aggregation inhibitors; quinolizidine derivatives; thioxanthenone and quinonic derivatives; single-entity multitarget agents.


**Abbreviations:** A $\beta$ ,  $\beta$ -amyloid; A $\beta$ (1-40),  $\beta$ -amyloid with 40 amino acids; A $\beta$ (1-42),  $\beta$ -amyloid with 42 amino acids; ACh, acetylcholine; AChE, acetylcholinesterase; AD, Alzheimer's disease; Ape-1, apurinic endonuclease-1; BChE, butyrylcholinesterase; CD, circular dichroism; ChEs, cholinesterases; DMSO, dimethylsulfoxide; DTNB, 5,5'-dithiobis(2-nitrobenzoic acid); HFIP, hexafluoroisopropanol; PAS, peripheral anionic site; PBS, phosphate buffer solution; SI, selectivity index; TEM, transmission electron microscopy; ThT, thioflavin T.

## 1. Introduction

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of aggregates of  $\beta$ -amyloid (A $\beta$ ) and hyperphosphorylated tau proteins leading to the formation of extracellular amyloid plaques and intracellular fibrillary tangles, respectively. A $\beta$  exists as a mixture of two prevalent peptides, A $\beta$ (1-40) and A $\beta$ (1-42), the latter being the most prompt to aggregate and the most cytotoxic in humans. Nowadays, it is accepted that soluble, low-molecular-weight oligomers formed as intermediate species in the aggregation process of A $\beta$  are responsible for neuronal damage and ultimately cell death. These events have been challenged by the "cholinergic hypothesis" that associates the main cognitive and behavioral symptoms of AD to the loss of cholinergic neurons and the consequent low synaptic levels of the neurotransmitter acetylcholine (ACh) [1]. Actually, current symptomatic therapies of AD rely on the restoration of ACh levels through the inhibition of acetylcholinesterase (AChE), the enzyme responsible for the hydrolysis of ACh at its catalytic anionic site (CAS). Indeed, it has been shown [2] that AChE, at its peripheral anionic binding site (PAS), may promote the aggregation of A $\beta$ ; therefore, dual binding site inhibitors of AChE may be beneficial in relieving cognitive and behavioral symptoms of AD by reducing both ACh hydrolysis and A $\beta$  aggregation. In progressive AD, AChE levels in the brain decline while butyrylcholinesterase (BChE) levels progressively increase; BChE is also able to hydrolyze ACh, even if at lower rate. Selective BChE inhibitors have been reported to increase the ACh level in the brain and also reduce the formation of A $\beta$  [3].

To obtain novel dual cholinesterase (ChE) inhibitors, or rather BChE selective inhibitors, a few years ago [4] we prepared a number of compounds derived from phenothiazine and other related tricyclic systems linked by different kinds of spacers to the bulky, lipophilic and strongly basic quinolizidine ring. It is worth noting that even simple derivatives of the quinolizidine ring (that differentiates the novel compounds from the classic BChE inhibitors such as ethopropazine and

Astra1397 [5]) are endowed with some anti-ChE activity [6]. All the examined compounds [4] exhibited activity against both ChEs, but inhibition of BChE was generally stronger, with sub-micromolar  $IC_{50}$  values for most of them. 9-[(Quinolizidin-1-yl)methyl]thioxanthene (9-lupinylthioxanthene; **A**) was the most potent and selective inhibitor for BChE ( $IC_{50}$ = 0.15  $\mu$ M; SI= 47; SI is the selectivity index measured as the ratio  $IC_{50}AChE/IC_{50}BChE$ ). The elongation of the spacer improved the inhibition of AChE; however, this prevailed over BChE inhibition only for 6-chloro-2-methoxy-9-{N-[3-(quinolizidin-1-yl)methylthio]propylamino}acridine **B** ( $IC_{50}$ = 0.22  $\mu$ M; SI= 0.32).




Aside from the valuable inhibitory activity of ChEs, several of the studied compounds have shown additional pharmacological properties that could reinforce central cholinergic activity or improve certain cognitive performances in AD. Pursuing the goal to obtain ChE inhibitors with additional pharmacological properties of potential utility in the control of symptoms and/or progression of AD, we turned our attention to quinolizidinyl derivatives of: a) other tricyclic systems as thioxanthen-9-one and xanthenone, and b) bi- and tricyclic quinoid compounds (naphtho- and anthraquinones). Our main goal was the identification of new and potent ChE inhibitors exhibiting also a direct inhibition of  $A\beta$  self-aggregation.

The first subgroup of examined compounds is structurally related to lucanthone (**C**), a drug largely used in the past for the treatment of schistosomiasis [7], which since 1980 has been under study as an antitumor agent [8]. Its activity has been related to DNA intercalation, the inhibition of nucleic acid biosynthesis, topoisomerase II and apurinic endonuclease-1 (Ape-1) without affecting its redox activity [9]. More recently, lucanthone has also been shown to disrupt lysosomal function and to inhibit cell autophagy [10]. Autophagy is a degradative process that eliminates anomalous proteins and protein aggregates, thereby maintaining protein homeostasis. Under metabolic and/or hypoxic stress conditions, cells may undergo self-digestion to generate ATP and other essential molecules, thus promoting their own survival. On the other hand, it has been shown that  $A\beta$  can be generated in autophagic vacuoles [11], thus counterbalancing the neuroprotective potential of autophagy. While inhibition of autophagy has been demonstrated to play a role in cancer therapy (by


accelerating death of cancer cells typically in a state of nutrient and oxygen deprivation), adequate autophagy modulation might reduce the production of A $\beta$  in AD. Besides the possible reduction of A $\beta$  production by autophagy modulation, of particular relevance for the present work is lucanthone's potent inhibition of horse serum BChE (IC<sub>50</sub>= 0.15  $\mu$ M) [12] associated with only a modest inhibition of electric eel AChE (25-40% at 10  $\mu$ M) rendering this drug an interesting multitarget lead for AD therapy. The second subgroup of compounds is related to several naphtho- and anthraquinones that have been shown to affect important biological targets. Specifically, compound E3330 and related naphthoquinones [9b, 13] inhibit (in contrast with lucanthone) the redox function of Ape-1 while, more importantly, other naphthoquinones, as juglone [**D**], inhibit A $\beta$  oligomerization [14] without inhibiting fibrillization. Oligomerization and fibrillization might be seen as independent pathways and soluble, low-molecular-weight amyloid oligomers are the primary toxic species in neurodegenerative diseases [15]. The linking of a naphthoquinone moiety to the amino group of tryptophan produced potent inhibitors (**E**) of both oligomerization and fibrillization [16]. Antitumor anthraquinones such as rubicins (**F**) [17] and xantrones (e.g., mitoxantrone (**G**) and pixantrone (**H**) [18]) proved to be effective A $\beta$  oligomerization inhibitors, with the latter also reducing the cellular toxicity of A $\beta$  peptide.

Interestingly, poly-hydroxyanthraquinones (as emodin (**I**), 1,2,5,8-tetrahydroxyanthraquinone, and rubicins) are also able to inhibit tau protein aggregation and even to dissolve preformed aggregates, precluding neurofibrillary tangle formation in AD [19]. Other anthraquinones substituted with ( $\omega$ -*tert*-amino)acylamino chains, such as 2,7-bis[(3-*tert*-aminopropionyl)amino]anthraquinones (**L**), exhibit high cytotoxicity against a panel of human cancer cell lines, by specifically targeting G-quadruplex and inhibiting telomerase [20]. The association of telomerase shortening and cellular senescence is well demonstrated *in vitro* and evidence is growing for such an association also *in vivo* [21]. Telomerase knockout mice exhibit reduced neurogenesis, loss of neurons, and short-term memory deficit. On the contrary, in aging APP23 transgenic mice, telomerase shortening has been shown to reduce the progression of amyloid plaque pathology and improve spatial learning ability [22].




**Chart 1**

Based on these premises, we have now combined structural features of the previously studied ChE inhibitors [4] with those of thioxanthenone and quinoid derivatives in an attempt to obtain “single entity multitarget” agents of potential interest in the treatment of AD. The entire set of studied compounds is represented in Charts 2 and 3.



**Chart 2**



**Chart 3**

In most of these compounds a quinolizidine ring is linked to an aromatic amino group through a polymethylene chain of variable length. The effect of the length of the linker on biological activities has been explored on the basis of previous findings of ours and others [23-26], coming from the study from homo- and hetero-dimeric dual binding site ChE inhibitors; the optimal distance between the two moieties, interacting at the catalytic and peripheral anionic sites, was associated to the presence of 6-8 methylenes tethering the two moieties.

The elongation of the spacer between the quinolizidine ring and the aromatic system requires the preparation of long chain  $\omega$ -(quinolizidin-1-yl)alkylamines. However, for compounds with more than 3 methylenes, the synthesis may result time consuming and we resorted to the use of  $\omega$ -{[(quinolizidin-1-yl)methyl]thio}alkylamines, taking into account the well known bioisosterism of a  $\text{CH}_2$  unit to an S atom.


## 2. Results and discussion

### 2.1. Chemistry

Twenty of the evaluated compounds were already described by some of us (**1-3**, **6-11**, **16**, **17** [27]; **23-28**, **31-33** [28] and assayed as antileukemic [27, 28] and antimicrobial agents [29]. Compound **30** was previously described by Elslager et al. [30].


The fifteen novel compounds (**4**, **5**, **12-15**, **18-22**, **29**, **34-36**) were prepared with the same methods used for the preparation of the above known compounds, with minor modifications. Thus, for the synthesis of compounds **4** and **5**, the 1-chloro-4-methylthioxanthen-9-one [31] was reacted with 3-[[*(1R,9aR)*-(octahydro-2*H*-quinolizin-1-yl)methyl]thio]propan-1-amine [32] or (*1R,9aR*)-(octahydro-2*H*-quinolizin-1-yl)methanthiole (thiolupinine) [33] in Dowtherm A in the presence of Cs<sub>2</sub>CO<sub>3</sub> (Scheme 1). 1-Chloro-4-methylxanthen-9-one, prepared according to [7a], was reacted with the suitable quinolizidinylalkylamine [34] or *N,N*-diethyl-1,3-propylenediamine to give **20-22** (Scheme 2).

For the synthesis of compounds **12-15**, it was necessary to first prepare 1-chloro-7-methoxy-4-nitrothioxanthen-9-one [35] by reacting 4-methoxythiophenol with 2,6-dichloro-3-nitrobenzoic acid and then forming the thioxanthenone ring by refluxing the formed diphenyl thioether with trifluoroacetic acid and trifluoroacetic anhydride. Finally the side chains were introduced, as usual, by reacting the obtained chlorothioxanthenone with the quinolizidinylalkylamines [34] or *N,N*-diethyl-1,3-propylenediamine (Scheme 2).



**Scheme 1.** Reagents and conditions: a) Dowtherm A, Cs<sub>2</sub>CO<sub>3</sub>, 170°C, 5h.







**Scheme 2.** Reagents and conditions: a) chlorocompound/amine ratio 1:2, 170°C, 6h.

The nitro compounds **13** and **15** were reduced, in ethanol solution, with SnCl<sub>2</sub> and conc. HCl to the corresponding amino compounds **18** and **19** (Scheme 3).

2,3-Dichloro-1,4-naphthoquinone and 1-chloro-9,10-anthraquinone were heated with 3-{[(1*R*,9*aR*)-(octahydro-2*H*-quinolizin-1-yl)methyl]thio}propan-1-amine [32], or *N,N*-diethyl-1,3-propylenediamine, or (1*R*,9*aR*)-(octahydro-2*H*-quinolizin-1-yl)methanthiole (thiolupinine) [33] to obtain the naphthoquinone **29** and the anthraquinones **34-36** (Scheme 4).



**Scheme 3.** Reagents and conditions: a) SnCl<sub>2</sub>, conc. HCl, EtOH, reflux 6h.



**Scheme 4.** Reagents and conditions: a) chlorocompound/amine ratio 1:1, 170°C, 6h.

## 2.2. Biological assays.

Inhibitory activities on AChE (either from electric eel and recombinant human) and BChE (from equine serum) were determined by the spectrophotometric method of Ellman [36] and are reported in Tables 1 and 2 as  $IC_{50}$  ( $\mu$ M) for the most active compounds, or as percentage of inhibition at 10  $\mu$ M for low active (i.e., <50%) compounds.

In vitro inhibition of A $\beta$ (1–40) aggregation was assessed following a previously reported ThT fluorescence-based method involving the use of hexafluoroisopropanol (HFIP) as aggregation enhancer [37]. For the most active compounds ( $\geq 80\%$  A $\beta$  aggregation inhibition)  $IC_{50}$  values were determined under the same assay conditions as already described [37]; data are reported in Table 1. In order to confirm the activity of these new classes of compounds, compound **2** was tested for its inhibitory activity also on A $\beta$ (1–42) aggregation.

## 2.3. Transmission electron microscopy (TEM) and circular dichroism (CD) spectroscopy

Aggregation kinetics were followed simultaneously for a free incubation sample of A $\beta$ (1–40), 50  $\mu$ M, and a co-incubated sample with the most active inhibitor **2** at 25  $\mu$ M concentration. Incubation conditions were slightly modified from those used in the screening assay, in order to achieve a slow and complete A $\beta$  aggregation within seven days, avoiding the use of HFIP, in PBS at the temperature of 37 °C. DMSO was replaced with ethanol as the co-solvent (5% v/v).

TEM analysis was performed at 48,000-fold magnification for samples of co-incubated A $\beta$ (1–40) (50  $\mu$ M) with compound **2** (25  $\mu$ M), compared with a reference free incubation sample of A $\beta$ . CD

spectra were recorded in the spectral range 195–250 nm, following the conformational random coil to  $\beta$ -sheet transition as revealed by the increase of the negative peak of CD signal at 217 nm.

#### 2.4. Structure-activity relationships of ChEs and A $\beta$ aggregation inhibition

The inhibitory activities of lucanthone and compounds **1–36** toward AChE, BChE and A $\beta$ (1–40) aggregation are listed in Table 1, together with those of donepezil [38] and quercetin [39] used as reference compounds. Typical dose-response curves are reported for compound **2** in Figure 1. As a common option in the screening of small chemical libraries of A $\beta$  aggregation inhibitors, we decided to use A $\beta$ (1–40) instead of the more toxic and aggregation-prone A $\beta$ (1–42). To confirm the results reported in Table 1, we also decided to test the derivative **2** in the inhibition of A $\beta$ (1–42) aggregation, obtaining the same inhibitory response (Fig. 3B).




Figure 1. Inhibition dose-response curves of compound **2** for AChE (A), BChE (B), and A $\beta$ (1-40) (C).

All tested compounds exhibited interesting inhibitory potencies on both AChE and BChE. The  $IC_{50}$  values were in the low micromolar or sub-micromolar range for at least one enzyme, but often for both of them. It is worth noting that two compounds even reached nanomolar potency: the long side chain thioxanthenone derivative **4**, which exhibited an  $IC_{50}$  for BChE = 88 nM, and the naphthoquinone derivative **28**, showing an  $IC_{50}$  for AChE = 11 nM, which resulted comparable to or even more potent than donepezil ( $IC_{50}$  = 20 nM; for rat brain AChE:  $IC_{50}$  = 6.7 nM [38]). Along with the most potent A $\beta$  inhibitor **2**, compound **28** was also tested on human AChE (hAChE), and inhibitory potencies (reported in Table 2) were in the activity range determined for electric eel AChE (eeAChE). Evaluation of inhibition kinetics of **28** on hAChE indicated a reversible, mixed-mode type, as expected for dual binding site inhibitors of AChE [40], with a  $K_i$  equal to 0.116  $\mu$ M (Figure 2).




Figure 2. Lineweaver–Burk plot of inhibition kinetics of **28**: reciprocals of enzyme activity (human AChE) vs. reciprocals of substrate (S-acetylthiocholine) concentration in the presence of different concentrations (0–50 nM) of inhibitor.

Indeed, all the tricyclic thioxanthenone derivatives are dual, though generally BChE-preferring inhibitors (with the exception of compounds **14** and **15**), while the naphthoquinone derivatives are dual AChE-preferring inhibitors, reaching a 1000-fold selectivity in cited compound **28**. The tricyclic anthraquinone derivatives exhibited a balanced dual inhibitory activity, with an alternant slight preference for AChE or BChE.

At a concentration of 100  $\mu$ M all compounds, except two (**25** and **26**), significantly inhibited the aggregation of A $\beta$ ; more importantly, 24 of 37 compounds displayed IC<sub>50</sub> values in the range of 0.84–31  $\mu$ M, with a mean of 11.4  $\mu$ M. Of these compounds **19**, **1** and **4** were thioxanthenone, xanthenone, and anthraquinone derivatives, respectively.

The 10 compounds for which it was not possible to calculate the IC<sub>50</sub> (seven are naphthoquinone derivatives), still inhibited A $\beta$  aggregation by 27–66% at a 100  $\mu$ M concentration. Once more, the size of the aromatic substructures (tri- versus bi-cyclic ring system) seems to have a higher influence on the biological activity than their chemical nature. It is worth noting that compound **2** exhibited a potency (IC<sub>50</sub>= 0.84  $\mu$ M) close to that of quercetin (IC<sub>50</sub>= 0.82  $\mu$ M), a reference anti-amyloidogenic compound.

The inhibition of A $\beta$  aggregation is commonly associated (lucanthonone and compounds **2-4**, **6-21**, **29**, **31-34** and **36**) with the simultaneous elevated inhibition of AChE and BChE, the latter of which is generally higher than the former (20 of 26 compounds). Moderate inhibition of A $\beta$  aggregation

was still observed for compound **1**, even if only the BChE was moderately inhibited ( $IC_{50}= 6.1 \mu M$ ) compared to AChE (34% inhibition at  $10 \mu M$ ).

In contrast, when AChE inhibition ( $IC_{50}$  range  $0.011-5.8 \mu M$ ) largely prevailed over BChE inhibition (affinity ratio from 10 to 1000), as observed for naphthoquinones (**23-30**), A $\beta$  aggregation was poorly inhibited or not affected at all. Two compounds (**5** and **22**) endowed with dual ChE inhibition, and specifically with sub-micromolar  $IC_{50}$  for BChE inhibition, were poorly active against A $\beta$  aggregation (46% and 55% inhibition, respectively, at  $100 \mu M$ ), indicating that other factors play a role in determining this biological activity. However, it is important to emphasize that some of the presently studied compounds inhibited the ChEs and A $\beta$  aggregation with relatively close potencies, which is a basic requisite for the potential development of therapeutic agents exhibiting multitarget activity. Thus, the most relevant inhibitors compared favorably with the reference compounds donepezil and quercetin, which are among the most potent compounds for the inhibition of ChEs and A $\beta$  aggregation, respectively. Donepezil, a more potent AChE inhibitor than BChE, is practically devoid of inhibitory activity on direct A $\beta$  aggregation, whereas a weak inhibition resulted from its binding at the PAS of AChE (22% inhibition at  $100 \mu M$  [41]). On the other hand, quercetin (to which some of the thioxanthenone derivatives are comparable in potency as A $\beta$  aggregation inhibitors) was inactive as a ChE inhibitor (Table 1).

Concerning further aspects of structure-activity relationships, it has already been observed that the tricyclic compounds (thioxanthenone, xanthenone, and anthraquinone derivatives) exhibited rather close patterns of biological activity (dual, but BChE-preferring, and A $\beta$  aggregation inhibitory activities). In particular, anthraquinone derivatives resembled the thioxanthenone and xanthenone derivatives more than the chemically similar, but smaller, bicyclic naphthoquinone derivatives, which exhibited dual, but AChE-preferring inhibitory activity and quite modest activity on A $\beta$  aggregation. The tricyclic (hetero)aromatics are most likely capable of establishing stronger hydrophobic,  $\pi-\pi$  stacking and electrostatic interactions with the sequence of amino acids H<sub>14</sub>QKLVFF<sub>20</sub> of A $\beta$ , with the highest propensity to aggregate [42], than the bi-cyclic system. The same tricyclic systems seemed to guarantee better interactions at the external site of BChE than on the PAS of AChE.

Within the subset of tricyclic compounds, it was important to define the influence of the sulfur bridge that differentiates the thioxanthenone derivatives from the isosteric xanthenones. It is worth noting that a number of natural [43, 40] and synthetic [45-47] xanthenone derivatives have been shown to possess potent ChE inhibitory activity. However, all of them are characterized by the presence of several hydroxyl/methoxy groups or even carbamic ester function, and therefore are not

directly comparable with lucanthone and the thioxanthenone derivatives considered herein. The comparison of compounds **1**, **3** and **C** (lucanthone) with the corresponding compounds **20-22** indicated that the sulfur bridge consistently enhances the inhibition of A $\beta$  aggregation, while the oxygen bridge seems more suited to the inhibition of ChEs, particularly AChE.

The compounds bearing quinolizidine moieties generally display higher activities than the open dialkylaminoalkyl analogues (compare the following groups of compounds: **1-4** vs. **C**; **12-14** vs. **15**; **18** vs. **19**; **20**; **21** vs. **22**; **26-29** vs. **30** and **31-34** vs. **35**). The few exceptions to such a trend mainly regard AChE and, more occasionally, BChE inhibition, suggesting that other dialkylaminoalkyl chains might give rise to more valuable activities in ChE inhibition. On the other hand, the bulky and highly lipophilic quinolizidine moiety appears particularly suited to promote the inhibition of A $\beta$  aggregation, besides that of the ChEs.

Among the thioxanthenone and xanthenone derivatives it has been observed that the increase of the length of the linker between the 1-amino group and the quinolizidine nucleus produced an increase of activity. Examples of the few exceptions to this trend are represented by the greater BChE inhibition on the part of 4-nitro-1-(quinolizidinylmethylamino)thioxanthenone **10** ( $IC_{50}$ = 0.3  $\mu$ M) versus 1-(quinolizidinylpropylamino) homolog **11** ( $IC_{50}$ = 0.98  $\mu$ M) and, more so, by the higher inhibition of A $\beta$  aggregation by 4-methyl-1-(quinolizidinyethylamino)thioxanthenone (**2**,  $IC_{50}$ = 0.84  $\mu$ M) compared to homologs **3** and **4** ( $IC_{50}$ = 4.3  $\mu$ M). In addition, among the quinone compounds the polymethylene linker elongation tended to enhance the potencies of ChE inhibition; however, a remarkable 37-fold reduction of AChE inhibition was observed when the tri-methylene linker of **28** ( $IC_{50}$  = 0.011  $\mu$ M) was further elongated (**29**,  $IC_{50}$ = 0.41  $\mu$ M).

Concerning the inhibition of A $\beta$  aggregation, the increasing length of the linker in the anthraquinone derivatives **31**, **33**, and **34** (1 $\rightarrow$ 3 $\rightarrow$ 5 atoms, respectively), produced only a moderate effect ( $IC_{50}$ = 6.4, 9.7, and 8.3  $\mu$ M, respectively), whereas an unexpected net reduction of potency was observed when the linker was constituted of two methylene groups (**32**,  $IC_{50}$  = 31  $\mu$ M).

The nature of the substituent in position 4 of the thioxanthenone ring is important for biological activity. 4-Nitro and 4-amino are less favorable substituents than 4-methyl for ChE inhibitory activity, while the influence is somewhat more variable when A $\beta$  aggregation is accounted for. The additional presence of a 7-methoxy group often improves the activity, though several exceptions have been observed. The introduction of a chlorine atom to the naphthoquinone derivatives (**26-29**) clearly enhanced the potency of ChE inhibition, while its effect on A $\beta$  aggregation was rather modest.

Finally, the exchange of the imino group on position 1 of thioxanthenone for a sulfur bridge (compare **1** with **5**) improved the inhibitory activity on the ChEs; however, this effect did not hold for A $\beta$  aggregation. The same structural modification in anthraquinone derivatives consistently produced negative effects (compare **31** with **36**).

### 2.5. Kinetic studies of A $\beta$ aggregation

The inhibitory behavior of compound **2** in the A $\beta$ (1-40) aggregation cascade was investigated by means of circular dichroism (CD), thioflavin-T (ThT) fluorescence spectroscopy and transmission electron microscopy (TEM) analysis of aggregates. Aliquots from a coincubated sample of A $\beta$  (50  $\mu$ M) and **2** (25  $\mu$ M) in PBS containing 5% ethanol were collected and analyzed through seven days of incubation at 37 °C; a free incubation sample of A $\beta$  was used as reference. Besides its inhibitory potency (0.84  $\mu$ M, i.e. very similar to that of quercetin), compound **2** was also selected for its fair solubility, since it emerged among the most potent inhibitors (Table 1) as the most soluble in the assay medium in a preliminary UV-based solubility screening (data not shown).

The ThT fluorescence data (Fig. 3A) revealed a net effect of **2** in A $\beta$ (1-40) fibrillization, with a massive inhibition of the final fibril content. The time course of aggregation exhibited the typical sigmoidal shape, with an exponential growth of ThT fluorescence between days 1 and 3, whereas the coincubated sample revealed a similar, though considerably flattened, sigmoidal shape. The apparent difference in inhibitory potency of **2** (80% of inhibition of ThT fluorescence at 25  $\mu$ M concentration) might be compatible with its submicromolar value of IC<sub>50</sub>, since incubation experimental conditions for time course experiment were significantly different from those used in the preliminary screening.

To confirm the antifibrillogenic effect of **2**, we performed the same ThT fluorescence experiment with A $\beta$ (1-42) under the same assay conditions (Fig. 3B). Because the aggregating propensity of A $\beta$ (1-42) is substantially higher than A $\beta$ (1-40), we detected a sudden increase of fluorescence in the first 24 h for the free incubation sample, with the loss of the initial lag phase. Satisfactorily, coincubation with **2** resulted also in this case in a strong decrease of fluorescence that reached only 20% of the control value.




Figure 3. Typical time course experiment of aggregation kinetics of A $\beta$ (1-40) (A) and A $\beta$ (1-42) (B): controls (full lines) and co-incubated with **2** (dotted lines) in PBS/5% ethanol at 37 °C. Squares and circles represent ThT fluorescence and CD ellipticity at 217 nm, respectively. Values are displayed as percent of maximal values obtained from the controls.

CD spectra outlined a net  $\beta$ -sheet arrangement for both A $\beta$ (1-40) free and A $\beta$ /2 co-incubated samples, reaching almost 60% of the final  $\beta$ -sheet content in the first 2 days of incubation, as shown by the negative ellipticity band centered at 217 nm. CD spectra (not reported) of both samples accounted for a stepwise rearrangement of the secondary structure from initial random coil to final  $\beta$ -sheet, with a small difference for co-incubated A $\beta$ /2, displaying a residual content of random coil structure and a lower (80%) intensity of the  $\beta$ -sheet band. These data demonstrate that the antifibrillogenic activity displayed by this class of compounds is not related to the inhibition of the  $\beta$ -sheet arrangement, but rather to a different mechanism that we investigated by means of TEM to obtain visual proof of the shape and dimension of eventual aggregates.

The evolution of fibril formation for the same samples described above was detected at three time points: i.e., at the start (day 0), the third, and finally seventh day of incubation (Figure 4). Samples at day 0 were homogeneously devoid of any prefibrillar aggregate, both in the control (Fig. 4A) and in the co-incubated sample (Fig. 4D). At day 3, a network of fibrillar species was already visible in both control and co-incubated specimens (Figs. 4B, 4E), leading at day 7 to the massive formation of tangles (Figs. 4C, 4F). The amount of fibrillar species formed also in the presence of **2** suggested that the quenching of ThT fluorescence cannot be explained by the mere inhibition of fibril formation, but rather with a different structural arrangement that hampers ThT staining.






Figure 4. TEM micrographs of samples from aggregation kinetics of 50  $\mu\text{M}$   $\text{A}\beta(1-40)$  alone (A-C) or coincubated with 25  $\mu\text{M}$  **2** (D-F) in PBS/5% ethanol at 37  $^{\circ}\text{C}$ . Samples were collected at time point zero (A, D), 3 (B, E) and 7 days of incubation (C, F). Black scale bars indicate 100 nm.

For a sound explanation of these results, a statistical analysis was performed to determine the average diameter of fibrils formed at 3 and 7 days of incubation for both the control ( $d$ ) and coincubated ( $d'$ ) samples. At day 3, average  $d$  and  $d'$  were  $13.3 \pm 2.4$  nm and  $10.5 \pm 2.3$  nm, respectively. At day 7, the thickness of control fibrils slightly increased to  $13.8 \pm 3.1$  nm, while for the coincubated sample it was  $9.4 \pm 1.7$  nm. Such average diameters are fully compatible with those reported in the literature [48]; worthy of note is the difference of approximately 4 nm between  $d$  and  $d'$  of fibrils finally formed after 7 days. Visual inspection revealed that the fibrillar structures formed in the presence of the inhibitor appeared at any time to be more rigid, inhomogeneous and to curl compared to those of the control specimen. The loss of ThT staining could therefore be ascribed to a destabilizing effect of the inhibitor in the correct evolution and assembly of prefibrillar species into mature fibrils.

### 3. Conclusions

Based on the models of compounds previously described as capable of maintaining or restoring cell protein homeostasis and of inhibiting  $\text{A}\beta$  oligomerization, 37 thioxanthen-9-one, xanthen-9-one, naphtho- and anthraquinone derivatives were tested for the direct inhibition of  $\text{A}\beta$  aggregation and the inhibition of AChE and BChE. These compounds are characterized by the presence of basic side

chains, mainly quinolizidinylalkyl moieties, that have been recently shown to produce potent ChE inhibitors when linked to various bi- and tri-cyclic (hetero)aromatic systems [4].

With very few exceptions, all these compounds were able to display inhibitory activity on both AChE and BChE and on the spontaneous aggregation of A $\beta$ . In this regard, the time course of amyloid aggregation in the presence of **2** revealed that these compounds might act as destabilizers of mature fibrils rather than mere inhibitors of fibrillization. Their potential utility in the control of symptoms and/or progression of AD would therefore be confirmed only after an extensive biophysical evaluation of prefibrillar, oligomeric species (i.e., the true neurotoxic species of A $\beta$ ) interfered during the aggregation process.

Most compounds exhibited IC<sub>50</sub> values in the low micromolar or sub-micromolar range in the different biological activities; yet, single compounds even reached nanomolar potency (e.g., thioxanthenone derivative **4**, with IC<sub>50</sub>= 88 nM for the inhibition of BChE, and chloronaphthoquinone derivative **28** with IC<sub>50</sub>= 11 nM for AChE inhibition).

More importantly, many compounds inhibited one or both ChEs and A $\beta$  aggregation with similar potencies, thus fulfilling a fundamental requirement for a multitarget mechanism of action. Among these compounds, the thioxanthenone derivatives **2**, **4**, **7**, and **9**, and most of all **17**, as well as anthraquinones **33** and **34** warrant further investigations.

Interestingly, only a low/moderate toxicity is expected for the present compounds as it can be inferred from the results of their testing for anti-leukemic activity [27, 28]. Indeed, when injected i.p. for 5-9 consecutive days, in mice previously inoculated with leukemia P388 cells, they were tolerated in a dose range of 50-200 mg/Kg; compound **1** at 200 mg/Kg even prolonged the mice survival time of 24%. On the other hand it is observed that donepezil and galantamine, two current drugs for AD, display oral LD<sub>50</sub> in mice equal to 45 and 18.7 mg/Kg, respectively [49, 50].

## 4. Experimental protocols

### 4.1. Chemistry

Chemicals, solvents and reagents used for the syntheses were purchased from Sigma-Aldrich, Fluka or Alfa Aesar, and were used without any further purification. Column chromatography (CC): neutral alumina (Al<sub>2</sub>O<sub>3</sub>), activity 1 (Merck). Mps: Büchi apparatus, uncorrected. <sup>1</sup>H NMR spectra: Bruker Avance DPX-300 or Varian Gemini-200 spectrometers; CDCl<sub>3</sub>;  $\delta$  in ppm rel. to Me<sub>4</sub>Si as internal standard. *J* in Hz. Elemental analyses were performed on a Carlo Erba EA-1110 CHNS-O instrument in the Microanalysis Laboratory of the Department of Pharmacy of Genoa University.

#### 4.1.1. General procedure for the synthesis of compounds **4**, **5**, **12-15**, **20-22**, **29** and **34-36**.

A mixture of the suitable reactive chloroderivative (1-chloro-4-methyl-9H-xanthen-9-one; 1-chloro-7-methoxy-4-nitro-9H-thioxanthen-9-one; 2,3-dichloro-1,4-naphthoquinone; 1-chloro-9,10-anthraquinone) with the suitable aminocompound [(1*S*,9*aR*)-(octahydro-2*H*-quinolizin-1-yl)alkylamines [34]; 3-[[*(1R,9aR)*-(octahydro-2*H*-quinolizin-1-yl)methyl]thio]propan-1-amine [32]; (*1R,9aR*)-(octahydro-2*H*-quinolizin-1-yl)methanthiole (thiolupinine) [33]; *N,N*-diethyl-1,3-propylenediamine] was heated at 170°C in a closed tube for 6h. The ratio between chlorocompound/amine was 1:2 for compounds **12-15** and **20-22**, while was 1:1 for compounds **29** and **34-36**.

To synthesize compounds **4** and **5**, 1-chloro-4-methyl-9H-thioxanthen-9-one (2.3 mmol) was reacted with 3-[[*(1R,9aR)*-(octahydro-2*H*-quinolizin-1-yl)methyl]thio]propan-1-amine or thiolupinine in a ratio 1:1 and in solution of Dowtherm A (2 mL) and in the presence of Cs<sub>2</sub>CO<sub>3</sub> (2.3 mmol), heating at 170°C for 5h.

1-Chloro-4-methyl-9H-xanthen-9-one and 1-chloro-4-methyl-9H-thioxanthen-9-one were used as mixtures with the unreactive isomers as indicated in [7a] and [31].

In all cases at r.t. the mixture was triturated with 2N HCl and extracted with Et<sub>2</sub>O; then the acid solution was basified with 6N NaOH and exhaustively extracted with Et<sub>2</sub>O or CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was washed with water and, after drying (Na<sub>2</sub>SO<sub>4</sub>), evaporated affording a residue that was crystallized from the indicated solvent or purified by CC (Al<sub>2</sub>O<sub>3</sub>/Et<sub>2</sub>O or CH<sub>2</sub>Cl<sub>2</sub>). In the case of compounds **4**, **22**, **34** and **35** the oily residue was converted into the corresponding monohydrochloride with 1N ethanolic solution of HCl.

#### 4.1.1.1. - 4-Methyl-1-{3-[(*1R,9aR*)-(octahydro-2*H*-quinolizin-1-yl)methylthio]prop-1-yl-amino} -9H-thioxanthen-9-one (**4**)

Yield: 43%. Oil. CC(Al<sub>2</sub>O<sub>3</sub>/CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (200MHz, CDCl<sub>3</sub>): 0.94-2.22 (m, 16H, 14H of Q and 2H of CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>); 2.36 (s, CH<sub>3</sub>-Ar); 2.62-2.99 (m, 6H, 2H<sub>α</sub> near N of Q, 2H of CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-S and 2H of SCH<sub>2</sub>); 3.34-3.55 (m, 2H, NHCH<sub>2</sub>); 6.61 (d, *J*= 7.6, 1 arom. H). 7.21-7.68 (m, 4 arom. H); 8.52 (dd, *J*= 7.6, 0.9, 1 arom. H); 10.12 (s, NH, collapses with D<sub>2</sub>O). Anal. Calcd for C<sub>27</sub>H<sub>34</sub>N<sub>2</sub>OS<sub>2</sub>: C, 69.49; H, 7.34; N, 6.00; S, 13.74. Found: C, 69.71; H, 7.07; N, 6.28; S, 13.45. Monohydrochloride: M.p. 152-154°C (Et<sub>2</sub>O). Anal. Calcd for C<sub>27</sub>H<sub>34</sub>N<sub>2</sub>OS<sub>2</sub>+HCl: C, 64.45; H, 7.01; N, 5.57; S, 12.75. Found: C, 64.33; H, 7.09; N, 5.37; S, 12.00.

#### 4.1.1.2. 4-Methyl-1-[[*(1R,9aR)*-(octahydro-2*H*-quinolizin-1-yl)methyl]thio]-9H-thioxanthen-9-one (**5**)

Yield: 66%. M.p. 113-115°C (CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (200MHz, CDCl<sub>3</sub>): 1.04-2.33 (m, 14H of Q); 2.50 (s, CH<sub>3</sub>-Ar); 2.79-3.38 (m, 4H, 2H<sub>α</sub> near N of Q and 2H of SCH<sub>2</sub>); 7.24-7.82 (m, 5 arom. H); 8.60

(d,  $J = 7.6$ , 1 arom. H). Anal. Calcd for  $C_{24}H_{27}NOS_2$ : C, 70.38; H, 6.64; N, 3.42; S, 15.65. Found: C, 70.39; H, 6.67; N, 3.47; S, 15.26

4.1.1.3. 7-Methoxy-4-nitro-1- $\{[(1S,9aR)-(octahydro-2H-quinolizin-1-yl)methyl]amino\}$ -9H-thioxanthen-9-one (**12**)

Yield: 57%. M.p. 194-196°C (Et<sub>2</sub>O/pentane). <sup>1</sup>H NMR (200MHz, CDCl<sub>3</sub>): 1.11-2.42 (m, 14H of Q); 2.91-3.12 (m, 2H $\alpha$  near N of Q); 3.62-3.80 (m, 2H, NHCH<sub>2</sub>); 3.97 (s, 3H, OCH<sub>3</sub>); 6.78 (d,  $J = 9.2$ , 1 arom. H); 7.26-7.38 (m, 1 arom. H); 7.63 (d,  $J = 8.6$ , 1 arom. H); 7.97 (d,  $J = 2.8$ , 1 arom. H); 8.56 (d,  $J = 9.2$ , 1 arom. H); 12.03 (s, NH-Ar, collapses with D<sub>2</sub>O). Anal. Calcd for  $C_{24}H_{27}N_3O_4S$ : C, 63.56; H, 6.00; N, 9.26; S, 7.07. Found: C, 63.42; H, 5.96; N, 9.64; S, 6.85

4.1.1.4. 7-Methoxy-4-nitro-1- $\{[(1S,9aR)-(octahydro-2H-quinolizin-1-yl)ethyl]amino\}$ -9H-thioxanthen-9-one (**13**)

Yield: 67%. M.p. 170-173°C (Et<sub>2</sub>O/pentane). <sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>): 1.20-2.04 (m, 16H, 14H of Q and 2H of NHCH<sub>2</sub>CH<sub>2</sub>); 2.77-2.93 (m, 2H $\alpha$  near N of Q); 3.22-3.48 (m, 2H, NHCH<sub>2</sub>CH<sub>2</sub>); 3.96 (s, 3H, OCH<sub>3</sub>); 6.50 (d,  $J = 6.0$ , 1 arom. H); 7.00 (d,  $J = 6.0$ , 1 arom. H); 7.10-7.21 (m, 1 arom. H); 7.46 (d,  $J = 6.0$ , 1 arom. H); 7.98 (d,  $J = 2.0$ , 1 arom. H); 9.77 (s, NH-Ar, collapses with D<sub>2</sub>O). Anal. Calcd for  $C_{25}H_{29}N_3O_4S$ : C, 64.22; H, 6.25; N, 8.99; S, 6.86. Found: C, 64.19; H, 6.42; N, 8.99; S, 6.49.

4.1.1.5. 7-Methoxy-4-nitro-1- $\{[(1S,9aR)-(octahydro-2H-quinolizin-1-yl)prop-1-yl]amino\}$ -9H-thioxanthen-9-one (**14**)

Yield: 46%. M.p. 112-114°C (Et<sub>2</sub>O/pentane). <sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>): 1.12-2.18 (m, 16H, 14H of Q and 2H of CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>); 2.78-2.94 (m, 2H $\alpha$  near N of Q); 3.28-3.45 (m, 2H, NHCH<sub>2</sub>); 3.87 (s, 3H, OCH<sub>3</sub>); 6.57 (d,  $J = 6.0$ , 1 arom. H); 7.18-7.27 (m, 1 arom. H); 7.52 (d,  $J = 6.0$ , 1 arom. H); 7.85 (d,  $J = 2.0$ , 1 arom. H); 8.44 (d,  $J = 6.0$ , 1 arom. H); 11.86 (s, NH, collapses with D<sub>2</sub>O). Anal. Calcd for  $C_{26}H_{31}N_3O_4S$ : C, 64.84; H, 6.49; N, 8.72; S, 6.66. Found: C, 64.97; H, 6.39; N, 8.37; S, 6.87.

4.1.1.6. 1- $\{[3-(N,N-Dimethylamino)prop-1-yl]amino\}$ -7-methoxy-4-nitro-9H-thioxanthen-9-one (**15**)

Yield: 66%. M.p. 101-103°C (Et<sub>2</sub>O/pentane). <sup>1</sup>H NMR (200MHz, CDCl<sub>3</sub>): 1.19 (t,  $J = 7.0$ , 6H, N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>); 2.00-2.24 (m, 2H, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>N(C<sub>2</sub>H<sub>5</sub>)<sub>2</sub>); 2.60-2.94 (m, 6H, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>); 3.42-3.60 (m, 2H, NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>N(C<sub>2</sub>H<sub>5</sub>)<sub>2</sub>); 3.96 (s, 3H, OCH<sub>3</sub>); 6.68 (d,  $J = 9.8$ , 1 arom. H); 7.20-7.32 (m, 1 arom. H); 7.57 (d,  $J = 8.8$ , 1 arom. H); 7.89 (d,  $J = 2.8$ , 1 arom. H); 8.49 (d,  $J = 9.8$ , 1 arom. H); 11.96 (s, NH, collapses with D<sub>2</sub>O). Anal. Calcd for  $C_{21}H_{25}N_3O_4S$ : C, 60.70; H, 6.06; N, 10.11; S, 7.72. Found: C, 60.64; H, 6.00; N, 10.18; S, 7.41.

4.1.1.7. 4-Methyl-1- $\{[(1S,9aR)-(octahydro-2H-quinolizin-1-yl)methyl]amino\}$ -9H-xanthen-9-one (**20**)

Yield: 67%. M.p. 109-111°C (Et<sub>2</sub>O). <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>): 1.08-2.24 (m, 14H of Q); 2.36 (s, CH<sub>3</sub>-Ar); 2.81-2.96 (m, 2H<sub>α</sub> near N of Q); 3.30-3.60 (m, 2H of NHCH<sub>2</sub>); 6.42 (d, *J* = 9.8, 1 arom. H); 7.24-7.72 (m, 4 arom. H); 8.24 (d, *J* = 9.2, 1 arom. H); 9.38 (s, NH, collapses with D<sub>2</sub>O). Anal. Calcd for C<sub>24</sub>H<sub>28</sub>N<sub>2</sub>O<sub>2</sub>: C, 76.56; H, 7.50; N, 7.44. Found: C, 76.21; H, 7.38; N, 7.68.

4.1.1.8. 4-Methyl-1-[[*(1S,9aR)*-(octahydro-2*H*-quinolizin-1-yl)prop-1-yl]amino]-9*H*-xanthen-9-one (21)

Yield: 40%. M.p. 82-84°C (Et<sub>2</sub>O). <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>): 1.05-2.00 (m, 16H, 14H of Q and 2H of CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>); 2.37 (s, CH<sub>3</sub>-Ar); 2.86-3.14 (m, 2H<sub>α</sub> near N of Q); 3.18-3.36 (m, 2H, NHCH<sub>2</sub>); 6.36 (d, *J* = 8.4, 1 arom. H); 7.23-7.74 (m, 4 arom. H); 8.24 (d, *J* = 7.8, 1 arom. H); 9.38 (s, NH, collapses with D<sub>2</sub>O). Anal. Calcd for C<sub>26</sub>H<sub>32</sub>N<sub>2</sub>O<sub>2</sub>: C, 77.19; H, 7.97; N, 6.92. Found: C, 76.95; H, 8.20; N, 7.05.

4.1.1.9. 1-[[3-(*N,N*-Diethylamino)prop-1-yl]amino]-4-methyl-9*H*-xanthen-9-one (22)

Yield: 58%. Oil. CC(Al<sub>2</sub>O<sub>3</sub>/Et<sub>2</sub>O). <sup>1</sup>H NMR (200MHz, CDCl<sub>3</sub>): 1.07 (t, *J* = 7.4, 6H, N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>); 1.80-2.20 (m, 2H, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>N(C<sub>2</sub>H<sub>5</sub>)<sub>2</sub>); 2.35 (s, CH<sub>3</sub>-Ar); 2.40-2.78 (m, 6H, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>); 3.17-3.39 (m, 2H, NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>N(C<sub>2</sub>H<sub>5</sub>)<sub>2</sub>); 6.36 (d, *J* = 9.8, 1 arom. H); 7.20-7.71 (m, 4 arom. H); 8.23 (d, *J* = 9.4, 1 arom. H); 9.37 (s, NH, collapses with D<sub>2</sub>O). Monohydrochloride: M.p. 176-179°C (Et<sub>2</sub>O). Anal. Calcd for C<sub>21</sub>H<sub>26</sub>N<sub>2</sub>O<sub>2</sub>+HCl: C, 67.28; H, 7.26; N, 7.47. Found: C, 67.29; H, 7.51; N, 7.63.

4.1.1.10. 3-Chloro-2-[[*(1S,9aR)*-(octahydro-2*H*-quinolizin-1-yl)prop-1-yl]amino]-1,4-naphthoquinone (29)

Yield: 63%. M.p. 96-97°C (CH<sub>2</sub>Cl<sub>2</sub>). CC(Al<sub>2</sub>O<sub>3</sub>/CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (200MHz, CDCl<sub>3</sub>): 0.94-2.24 (m, 16H, 14H of Q and 2H of CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>); 2.64 (t, *J* = 6.4, 2H, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>S) 2.72-3.04 (m, 4H, 2H<sub>α</sub> near N of Q and 2H of SCH<sub>2</sub>); 3.88-4.12 (m, 2H, NHCH<sub>2</sub>); 6.23 (s, NH, collapses with D<sub>2</sub>O); 7.59-7.82 (m, 2 arom. H); 7.98-8.24 (m, 2 arom. H); 9.82 (s, NH, collapses with D<sub>2</sub>O). Anal. Calcd for C<sub>23</sub>H<sub>29</sub>ClN<sub>2</sub>O<sub>2</sub>S: C, 63.80; H, 6.75; N, 6.47; S, 7.41. Found: C, 64.10; H, 6.49; N, 6.42; S, 7.08.

4.1.1.11. 1-[[3-[[*(1R,9aR)*-(octahydro-2*H*-quinolizin-1-yl)methylthio]prop-1-yl]amino]-9,10-anthraquinone (34)

Yield: 57%. Oil. CC(Al<sub>2</sub>O<sub>3</sub>/CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (200MHz, CDCl<sub>3</sub>): 0.94-2.26 (m, 16H, 14H of Q and 2H of CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>); 2.57-3.05 (m, 6H, 2H<sub>α</sub> near N of Q, 2H of CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-S and 2H of SCH<sub>2</sub>); 3.38-3.62 (m, 2H, NH-CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>); 7.12 (dd, *J* = 9.2, 1.6, 1 arom. H). 7.43-7.88 (m, 4 arom. H); 8.16-8.40 (m, 2 arom. H); 9.82 (s, NH, collapses with D<sub>2</sub>O). Anal. Calcd for C<sub>27</sub>H<sub>32</sub>N<sub>2</sub>O<sub>2</sub>S: C, 72.29; H, 7.19; N, 6.24; S, 7.15. Found: C, 72.03; H, 6.98; N, 6.47; S, 7.42. Monohydrochloride (higrosopic). Anal. Calcd for C<sub>27</sub>H<sub>32</sub>N<sub>2</sub>O<sub>2</sub>S+HCl+2H<sub>2</sub>O: C, 62.23; H, 7.16; N, 5.38; S, 6.15. Found: C, 62.48; H, 7.48; N, 5.60; S, 6.15.

4.1.1.12. 1-[[3-(N,N-Dimethylamino)prop-1-yl]amino]-9,10-anthraquinone (**35**)

Yield: 70%. Oil.  $\text{CC}(\text{Al}_2\text{O}_3/\text{Et}_2\text{O})$ .  $^1\text{H NMR}$  (300MHz,  $\text{CDCl}_3$ ): 1.46 (t,  $J = 7.4$ , 6H,  $\text{N}(\text{CH}_2\text{CH}_3)_2$ ); 2.26-2.44 (m, 2H,  $\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{C}_2\text{H}_5)_2$ ); 3.10-3.36 (m, 6H,  $\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{CH}_2\text{CH}_3)_2$ ); 3.54 (t,  $J = 7.4$ , 2H,  $\text{NHCH}_2\text{CH}_2\text{CH}_2\text{N}(\text{C}_2\text{H}_5)_2$ ); 7.06 (d,  $J = 8.8$ , 1 arom. H); 7.52-7.81 (m, 4 arom. H); 8.22 (d,  $J = 8.6$ , 2 arom. H); 12.24 (s, NH, collapses with  $\text{D}_2\text{O}$ ). Monohydrochloride: M.p. 224-226°C (EtOH/Et<sub>2</sub>O). Calcd for  $\text{C}_{21}\text{H}_{24}\text{N}_2\text{O}_2 + \text{HCl}$ : C, 67.64; H, 6.76; N, 7.51. Found: C, 67.44; H, 7.11; N, 7.44.

4.1.1.13. 1-[[1R,9aR)-(octahydro-2H-quinolizin-1-yl)methyl]thio]-9,10-anthraquinone (**36**)

Yield: 64%. M.p. 182-184°C (EtOH).  $^1\text{H NMR}$  (200MHz,  $\text{CDCl}_3$ ): 0.96-2.28 (m, 14H of Q); 2.71-2.98 (m, 2H $\alpha$  near N of Q); 3.06-3.21 (m, 2H of  $\text{SCH}_2$ ); 7.62-7.97 (m, 4 arom. H); 8.09-8.46 (m, 3 arom. H). Anal. Calcd for  $\text{C}_{24}\text{H}_{25}\text{NO}_2\text{S}$ : C, 73.62; H, 6.44; N, 3.58; S, 8.19. Found: C, 73.80; H, 6.06; N, 3.22; S, 8.01.

4.1.2. General procedure for the synthesis of compounds **18** and **19**.

To a stirred soln. of the 4-nitroderivative **13** or **15** (0.96 mmol) in EtOH (20 ml), a solution of  $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$  (0.76 g, 3.36 mmol) in conc. HCl (5 ml) was slowly added. The mixture was refluxed for 6 h and then concentrated *in vacuo*. The residue was taken up in  $\text{H}_2\text{O}$ , alkalized with 6N NaOH and repeatedly extracted with Et<sub>2</sub>O. After drying ( $\text{Na}_2\text{SO}_4$ ), the solvent was removed and the oily residue converted into the dihydrochloride.

4.1.2.1. 4-Amino-7-methoxy-1-[[1S,9aR)-(octahydro-2H-quinolizin-1-yl)ethyl]amino]-9H-thioxanthen-9-one (**18**)

Yield: 61%. Oil.  $^1\text{H NMR}$  (300MHz,  $\text{CDCl}_3$ ): 1.10-2.06 (m, 16H, 14H of Q and 2H of  $\text{NHCH}_2\text{CH}_2$ ); 2.75-2.90 (m, 2H $\alpha$  near N of Q); 3.08-3.42 (m, 4H, 2H of  $\text{NHCH}_2\text{CH}_2$  and 2H of  $\text{NH}_2\text{-Ar}$ , collapse with  $\text{D}_2\text{O}$ ); 3.86 (s, 3H,  $\text{OCH}_3$ ); 6.47 (d,  $J = 6.0$ , 1 arom. H); 6.95 (d,  $J = 6.0$ , 1 arom. H); 7.08-7.20 (m, 1 arom. H); 7.37 (d,  $J = 6.0$ , 1 arom. H); 7.93 (d,  $J = 2.0$ , 1 arom. H); 9.78 (s,  $\text{NH-Ar}$ , collapses with  $\text{D}_2\text{O}$ ). Dihydrochloride: M.p. 235-238°C (EtOH). Anal. Calcd for  $\text{C}_{25}\text{H}_{31}\text{N}_3\text{O}_2\text{S} + 2\text{HCl}$ : C, 58.82; H, 6.52; N, 8.23; S, 6.28. Found: C, 59.10; H, 6.73; N, 8.08; S, 6.36.

4.1.2.2. 4-Amino-1-[[3-(N,N-dimethylamino)prop-1-yl]amino]-7-methoxy-9H-thioxanthen-9-one (**19**)

Yield: 65%. Oil.  $^1\text{H NMR}$  (200MHz,  $\text{CDCl}_3$ ): 1.19 (t,  $J = 7.2$ , 6H,  $\text{N}(\text{CH}_2\text{CH}_3)_2$ ); 1.92-2.14 (m, 2H,  $\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{C}_2\text{H}_5)_2$ ); 2.57-2.98 (m, 6H,  $\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{CH}_2\text{CH}_3)_2$ ); 3.22-3.56 (m, 4H, 2H of  $\text{NHCH}_2\text{CH}_2\text{CH}_2\text{N}(\text{C}_2\text{H}_5)_2$  and 2H of  $\text{NH}_2\text{-Ar}$ , collapse with  $\text{D}_2\text{O}$ ); 3.94 (s, 3H,  $\text{OCH}_3$ ); 6.55 (d,  $J = 8.8$ , 1 arom. H); 7.04 (d,  $J = 8.8$ , 1 arom. H); 7.17 (dd,  $J = 8.8, 3.0$ , 1 arom. H); 7.46 (d,  $J = 8.8, 1$

arom. H); 8.00 (d,  $J= 2.8$ , 1 arom. H); 9.86 (s, NH, collapses with D<sub>2</sub>O). Dihydrochloride: M.p. 230-233°C (EtOH). Anal. Calcd for C<sub>21</sub>H<sub>27</sub>N<sub>3</sub>O<sub>2</sub>S+2HCl: C, 55.02; H, 6.38; N, 9.17; S, 6.99. Found: C, 55.20; H, 6.43; N, 9.08; S, 7.37.

#### 4.2. Biological tests

All reagents and enzymes were purchased from Sigma-Aldrich Italy, unless otherwise specified. For title compounds, the concentration which determined 50% inhibition of the tested activity (IC<sub>50</sub>) was determined by testing in duplicate 5–7 concentrations, ranging from 100 to 0.01 μM, and calculated by nonlinear regression of the response/log(concentration) curve, using GraphPad Prism® v. 5.01 software (La Jolla, CA, USA). Values were obtained as the mean from two/three independent experiments.

##### 4.2.1. Inhibition of cholinesterases

The in vitro inhibition assays of AChE, either from electric eel (463 U/mg) and human recombinant (2770 U/mg), and BChE from equine serum (13 U/mg) were run in phosphate buffer 0.1 M, pH 8.0. Acetyl- and butyrylthiocholine iodides were used, respectively, as substrates, and 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB) was used as the chromophoric reagent [36]. Inhibition assays were carried out on an Agilent 8453E UV-visible spectrophotometer equipped with a cell changer. Solutions of tested compounds were prepared starting from 10 mM stock solutions in DMSO, which were diluted with water to a final content of organic solvent always lower than 1%. AChE inhibitory activity was determined in a reaction mixture containing 100 μL of a solution of AChE (0.9 U/mL in 0.1 M phosphate buffer, pH 8.0), 100 μL of a 3.3 mM solution of DTNB in 0.1 M phosphate buffer (pH 7.0) containing 6 mM NaHCO<sub>3</sub>, 100 μL of a solution of the inhibitor (six to seven concentrations ranging from  $1 \times 10^{-8}$  to  $1 \times 10^{-4}$  M), and 600 μL of work buffer. After incubation for 20 min at 25 °C, acetylthiocholine iodide (100 μL of 5 mM aqueous solution) was added as the substrate, and AChE-catalyzed hydrolysis was followed by measuring the increase of absorbance at 412 nm for 5.0 min at 25 °C. BChE inhibitory activity was assessed similarly using butyrylthiocholine iodide as the substrate.

##### 4.2.2. Kinetic studies of hAChE inhibition

Kinetic studies were performed under the same incubation conditions above described, using six concentrations of substrate (from 0.033 to 0.2 mM) and four concentrations of inhibitor **28** (0–50 nM). Apparent inhibition constant and kinetic parameters were calculated within the 'Enzyme kinetics' module of Prism.

#### 4.2.3. Thioflavin T fluorescence spectroscopy analysis

To obtain batches of A $\beta$ (1–40) and A $\beta$ (1–42) free from preaggregates, commercial peptides (purity >95%; EzBiolab, Carmel, USA) were dissolved in HFIP, lyophilized and stored at -20 °C. The solution of ThT (25  $\mu$ M) used for fluorimetric measures was prepared in phosphate buffer 0.025 M, pH 6.0, filtered through 0.45  $\mu$ m nylon filters and stored at 4 °C. For A $\beta$ (1–40) inhibition, compounds were first tested at 100  $\mu$ M; test samples were prepared in phosphate buffered saline (PBS; 0.01 M, NaCl 0.1 M, pH 7.4), with 30  $\mu$ M A $\beta$  peptide concentration, and contained 2% HFIP and 10% DMSO. Blank samples were prepared for each concentration, devoid of peptide, and their fluorescence value subtracted from the corresponding fluorescence values of incubation samples. As the control, a sample of peptide was incubated in the same PBS/2% HFIP/10% DMSO buffer, without inhibitor. Incubations were run in triplicate at 25 °C for 2 h. Fluorimetric measures were performed in a 700  $\mu$ L cuvette with a Perkin–Elmer LS55 spectrofluorimeter, using FLWinlab program. 470  $\mu$ L of ThT solution were mixed with 30  $\mu$ L of sample, and the resulting fluorescence measured with parameters set as follows: excitation at 440 nm (slit 5 nm); emission at 485 nm (slit 10 nm); integration time 2 s. Biological activity was determined as percent of inhibitory activity  $V_i$  for each concentration, according to the formula:

$$V_i = 100 - [(F_i - F_b)/F_0] \times 100$$

where  $F_i$  is the fluorescence value of the sample,  $F_b$  its blank value, and  $F_0$  the fluorescence value of A $\beta$  control (already subtracted of its blank).

#### 4.2.4. A $\beta$ aggregation kinetics

Samples for time course experiments of A $\beta$ (1–40) and A $\beta$ (1–42) aggregation inhibition were prepared in PBS with 5% ethanol as co-solvent and incubated up to seven days at 37 °C. Final concentrations of A $\beta$  and **2** were 50  $\mu$ M and 25  $\mu$ M, respectively. A control sample of self-aggregating A $\beta$  was prepared in the same buffer/cosolvent conditions.

#### 4.2.5. TEM studies

The same samples prepared as in Section 4.2.3 were used for TEM analysis. For each sample, a little drop (20  $\mu$ L) of incubated sample solution was applied to carbon coated copper/rhodium grid (400 mesh; TAAB Laboratories Equipment Ltd, Aldermaston, Berks, GB). The coated grid was floated for 2 min on the sample drop and rinsed with 200  $\mu$ L of double distilled water. Negative staining was performed with 200  $\mu$ L of 2% w/v uranyl acetate solution (TAAB Laboratories



Equipment Ltd). After draining off the excess of staining solution by means of a filter paper, the specimen was transferred for examination in a Philips Morgagni 282D transmission electron microscope, operating at 60 kV. Electron micrographs of negatively stained samples were photographed on Kodak electron microscope film 4489 (Kodak Company, New York, USA) and analyzed with Image 1.38 software. Statistics of fibril diameters were obtained with Kaleidagraph (Sinergy Software) calibration software.

#### 4.2.6. CD spectroscopy analysis

CD spectra were recorded in the spectral range 195–250 nm, by using 0.1 cm path length quartz cells (280  $\mu$ L internal volume, from Hellma GmbH & Co KG, Milan, I) with a CD Jasco J-810 single beam spectropolarimeter. Control A $\beta$  and A $\beta$ /inhibitor coincubation samples were the same as in TEM studies. CD spectra were recorded at room temperature at 0.1 nm intervals with 4 nm bandwidth and 100 nm/min scan speed. The baseline was recorded with the buffer/ethanol blank or, for co-incubation experiments, with buffer/ethanol solution of inhibitor blank, and automatically subtracted from corresponding spectra.

## References

- [1] (a) R. Jacob-Roetne, H. Jacobsen, Alzheimer's disease: from Pathology to Therapeutic Approaches. *Angew. Chem. Int. Ed.* 48 (2009) 3030-3059. (b) A. Rauk, The chemistry of Alzheimer's disease. *Chem. Soc. Rev.* 38 (2009) 2698- 2715. (c) I. W. Hamley, The amyloid beta peptide: A chemist perspective. Role in Alzheimer's and fibrillization. *Chem. Rev.* 112 (2012) 5147-5192.
- [2] (a) A. Alvarez , F. Bronfman, C. A. Pérez, M. Vicente, J. Garrido, N. C. Inestrosa, Acetylcholinesterase, a senile plaque component, affects the fibrillogenesis of amyloid-beta-peptides. *Neurosci. Lett.* 201 (1995) 49-52. (b) N. C. Inestrosa, A. Alvarez, C. A. Pérez, R. D. Moreno, M. Vicente, C. Linker, O. I. Casanueva, C. Soto, J. Garrido, Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. *Neuron* 16 (1996) 881-891. (c) G. V. De Ferrari, M. A. Canales, I. Shin, L. M. Weiner, I. Silman, N. C. Inestrosa, A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation. *Biochemistry* 40 (2001) 10447-10457.
- [3] (a) E. Giacobini, Selective Inhibitors of Butyrylcholinesterase. *Drugs Aging* 18 (2001) 891-898. (b) N. H. Greig, T. Utsuki, Q.-S. Yu, X. Zhu, H. W. Holloway, T. A. Perry, B. Lee, D. H. Ingram, D. K. Lahiri, A new therapeutic target in AD treatment: attention to

- butyrylcholinesterase. *Curr. Med. Res. Opin.* 17 (2001)159-165. (c) A. L. Guillozet, J. F. Smiley, D. C. Mash, M. M. Mesulam, Butyrylcholinesterase in the life cycle of amyloid plaques. *Ann Neurol.* 42 (1997) 909-918.
- [4] B. Tasso, M. Catto, O. Nicolotti, F. Novelli, M. Tonelli, I. Giangreco, L. Pisani, A. Sparatore, V. Boido, A. Carotti, F. Sparatore, Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer disease. *Eur. J. Med. Chem.* 46 (2011) 2170-2184.
- [5] (a) B. J. Bayliss, A. Todrick, The use of a selective acetylcholinesterase inhibitor in the estimation of pseudocholinesterase activity in rat brain. *Biochem. J.* 62 (1956) 62-67. (b) A. Saxena, A. M. Riedman, X. Jiang, O. Lockridge, B. P. Doctor, Differences in active site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase. *Biochemistry* 36 (1997) 14642-14651. (c) R. Dahlbom, T. Ekstrand, 10-Aminoacylphenothiazines. I. Aminoacetyl and aminopropionyl derivatives. *Acta Chem. Scand.* 5 (1951) 102-114. (d) P. W. Elsinghorst, C. M. Gonzáles Tanarro, M. Gütschow, Novel heterobivalent tacrine derivatives as cholinesterase inhibitors with notable selectivity toward butyrylcholinesterase. *J. Med. Chem.* 49 (2006) 7540-7544.
- [6] (a) E. V. Rozengart, Bisalkaloid derivatives of dicarboxylic acids on the basis of lupinine, anabasine and cytisine as reversible cholinesterase inhibitors. *Dokl. Biochem. Biophys.* 388 (2003) 39-42; *Chem. Abstr.* 139 (2003) 223727. (b) N. E. Basova, B. I. Kormilitsyn, E. V. Rozengart, V. S. Saakov, A. A. Suvorov, Derivatives of lupinine and epilupinine as ligands of various cholinesterases. *Zh. Evol. Biokhim. Fiziol.* 48 (2012) 8-16; *Chem. Abstr.* 157 (2012) 701122. (c) R. T. Tlegenov, Kh. Khaitbaev, É. Tilyabaev, D. N. Dalimov, A. A. Abduvakhabov, K. U. Uteniyazov, Synthesis and anticholinesterase properties of new derivatives of lupinine and epilupinine. *Chem. Nat. Comp.* 27 (1991) 55-57.
- [7] (a) H. Mauss, Basically substituted xanthone and thioxanthone derivatives; Miracil, a new chemotherapeutic agent. *Chem. Ber.* 81 (1948) 19-31. (b) S. Archer, C. M. Suter, The Preparation of some 1-alkylamino- and dialkylaminoalkylaminothioxanthenes. *J. Am. Chem. Soc.* 74 (1952) 4296-4309. (c) S. Archer, L. B. Rochester, M. Jackman, Aminoalkylamino derivatives of xantone, acridones and anthraquinones. *J. Am. Chem. Soc.* 76 (1954) 588-591.
- [8] (a) S. Archer, K. J. Miller, R. Rej, C. Periana, L. Fricker, Ring-hydroxylated analogues of lucanthone as antitumor agents. *J. Med. Chem.* 25 (1982) 220-227. (b) S. Archer, R. Rej, Nitro and amino derivatives of lucanthone as antitumor agents. *J. Med. Chem.* 25 (1982) 328-331. (c) S. Archer, A. H. Zayed, R. Rej, T. A. Rugino, Analogues of hycanthone and lucanthone as antitumor agents. *J. Med. Chem.* 26 (1983) 1240-1246.

- [9] (a) M. D. Naidu, R. Agarwal, L. A. Pena, L. Cunha, M. Mezei, M. Shen, D. M. Wilson III, Y. Liu, Z. Sanchez, , P. Chaudhary, S. H. Wilson, M. J. Waring, Lucanthone and its derivative hycanthone inhibit apurinic endonuclease-1 (Ape1) by direct protein binding. *Plos one* 6 (2011) e23679. (b) M. L. Fishel, M. R. Kelley, The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventive target. *Mol. Aspect Med.* 28 (2007) 375-395.
- [10] J. S. Carew, C. M. Espitia, J. A. Esquivel II, D. Mahalingam, K. R. Kelly, G. Reddy, F. J. Giles, S. T. Nawrocki, Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis. *J. Biol. Chem.* 286 (2011) 6602-6613.
- [11] (a) Y.-T. Tung, B.-J. Wang, M.-K. Hu, W.-M. Hsu, H. Lee, W.-P. Huang, Y.-F. Liao, Autophagy, a double-edged sword in Alzheimer's disease. *J. Biosci.* 37 (2012) 157-165. (b) S. F. Funderburk, B. K. Marcellino, Z. Yue, Cell "self-eating" (autophagy) mechanism in Alzheimer's disease. *Mt. Sinai J. Med.* 77 (2010) 59-68.
- [12] J. B. Verdier, A. D. Wolfe, Butyrylcholinesterase inhibition by Miracil D and other compounds. *Biochem. Pharmacol.* 35 (1986) 1605-1608.
- [13] R. L. Nyland, M. Luo, M. R. Kelly, R. F. Borch, Design and synthesis of novel quinone inhibitors targeted to the redox function of apurinic/aprimidinic endonuclease 1/redox enhancing factor-1 (Ape1/Ref-1). *J. Med. Chem.* 53 (2010) 1200-1210.
- [14] M. Necula, R. Kaye, S. Milton, C. G. Glabe, Small molecule inhibitors of aggregation indicate that amyloid  $\beta$  oligomerization and fibrillization pathways are independent and distinct. *J. Biol. Chem.* 282 (2007) 10311-10324.
- [15] (a) C. Glabe, Amyloid accumulation and pathogenesis of Alzheimer's disease: significance of monomeric, oligomeric and fibrillar A $\beta$ . *Subcell. Biochem.* 38 (2005) 167-177. (b) J. Hardy, D. J. Selkoe, The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics. *Science* 297 (2002) 353-356. (c) E. Gazit, The role of prefibrillar assemblies in the pathogenesis of amyloid diseases. *Drug Fut.* 29 (2004) 613-619.
- [16] R. Scherzer, E. Gazit, D. Segal, Naphthoquinone derivatives useful for prevention of amyloid deposits and treatment of diseases involving amyloidogenesis. *Pat. WO 2010026592A1* (2010).
- [17] T. Bandiera, J. Lansen, C. Post, M. Varasi, Inhibitors of A $\beta$  peptide aggregation as potential anti-Alzheimer agents. *Curr. Med. Chem.* 4 (1997) 159-170.
- [18] R. Colombo, A. Carotti, M. Catto, M. Racchi, C. Lanni, L. Verga, G. Caccialanza, E. De Lorenzi, CE can identify small molecules that selectively target soluble oligomers of amyloid  $\beta$  protein and display antifibrillogenic activity. *Electrophoresis* 30 (2009) 1418-1429.

- [19] M. Pickhardt, Z. Gazova, M. von Bergen, J. Khlistunova, Y. Wang, A. Hascher, E.-M. Mandelkow, J. Biernat, E. Mandelkow, Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments *in vitro* and in cells. *J. Biol. Chem.* 280 (2005) 3628-3635.
- [20] (a) P. J. Perry, S. M. Gowan, A. P. Reszka, P. Polucci, T. C. Jenkins, L. R. Kelland, S. Neidle, 1,4- and 2,6-Disubstituted amidoanthracene-9,10-dione derivatives as inhibitors of human telomerase. *J. Med. Chem.* 41 (1998) 3253-3260. (b) P. J. Perry, A. P. Reszka, A. A. Wood, M. A. Read, S. M. Gowan, N. S. Dosanjh, J. O. Trent, T. C. Jenkins, L. R. Kelland, S. Neidle, Human telomerase inhibition by regioisomeric disubstituted amidoanthracene-9,10-diones. *J. Med. Chem.* 41 (1998) 4873-4884.
- [21] A. Ahmed, T. Tollefsbol, Telomers and telomerase: basic science implications for aging. *J. Am. Geriatr. Soc.* 49 (2001) 1105-1109.
- [22] H. Rolyan, A. Scheffold, A. Heinrich, Y. Begus-Nahrman, B. H. Langkopf, S. M. Hölter, D. M. Vogt-Weisenhorn, B. Liss, W. Wurst, D. C. Lie, D. R. Thal, K. Biber, K. L. Rudolph, Telomere shortening reduces Alzheimer's disease amyloid pathology in mice. *Brain* 134 (2011) 2044-2056.
- [23] F. Leonetti, M. Catto, O. Nicolotti, L. Pisani, A. Cappa, A. Stefanachi, A. Carotti, Homo- and hetero-bivalent edrophonium-like ammonium salts as highly potent, dual binding site AChE inhibitors. *Bioorg. Med. Chem.* 16 (2008) 7450-7456.
- [24] A. Conejo-García, L. Pisani, M. C. Núñez, M. Catto, O. Nicolotti, F. Leonetti, J. M. Campos, M. A. Gallo, A. Espinosa, A. Carotti, Homo- and hetero-dimeric bis-quaternary heterocyclic ammonium salts as potent acetyl- and butyryl-cholinesterase inhibitors: a systematic investigation of the influence of linker and cationic heads over affinity and selectivity. *J. Med. Chem.* 54 (2011) 2627-2645.
- [25] H. Haviv, D. M. Wong, I. Silman, J. L. Sussman, Bivalent ligands derived from Huperzine A as acetylcholinesterase inhibitors. *Curr. Top. Med. Chem.* 7 (2007) 375-387.
- [26] P. W. Elsinghorst, C. M. Tanarro, M. Gütschow, Novel heterobivalent tacrine derivatives as cholinesterase inhibitors with notable selectivity toward butyrylcholinesterase. *J. Med. Chem.* 49 (2006) 7540-7554.
- [27] C. Boido Canu, G. Iusco, V. Boido, F. Sparatore, A. Sparatore, Synthesis and antileukemic activity of 1-[(quinolizidinylalkyl)amino]4/7-R-thioxanthen-9-ones. *Farmaco* 44 (1989) 1069-1082.

- [28] C. Boido Canu, V. Boido, F. Sparatore, Preparation and antileukemic activity of quinolizidinylalkyl-derivatives of naphthoquinone and anthraquinone. *Boll. Chim. Farm.* 128 (1989) 208-211.
- [29] A. Sparatore, M. Veronese, F. Sparatore, Quinolizidine derivatives with antimicrobial activity. *Farmaco, Ed. Sci.* 42 (1987) 159-174.
- [30] E. F. Elslager, L. M. Werbel, D. F. Worth, Synthetic schistosomicides. XIV. 1,4-naphthoquinone mono(O-acyloximes), 4-amino-1,2-naphthoquinones, 2-amino-3-chloro-1,4-naphthoquinones, and other naphthoquinones. *J. Med. Chem.* 13 (1970) 104-109.
- [31] F. Ullmann, O. von Glenck, Thioxanthone and benzophenonesulfone series. *Ber.* 49 (1916) 2487-2514.
- [32] V. Villa, M. Tonelli, S. Thellung, A. Corsaro, B. Tasso, F. Novelli, C. Canu, A. Pino, K. Chiovitti, D. Paludi, C. Russo, A. Sparatore, A. Aceto, V. Boido, F. Sparatore, T. Florio. Efficacy of Novel Acridine Derivatives in the Inhibition of hPrP90-231 Prion Protein Fragment Toxicity. *Neurotox. Res.* 19 (2011) 550-574.
- [33] F. Novelli, F. Sparatore, Thiolutin and some derivatives of pharmacological interest. *Farmaco* 48 (1993) 1021-1049.
- [34] V. Boido, A. Boido, C. Boido Canu, F. Sparatore, Quinolizidinylalkylamines with antihypertensive activity. *Farmaco, Ed. Sci.* 34 (1979) 673-687.
- [35] H. D. H. Showalter, M. M. Angelo, E. M. Berman, G. D. Kanter, D. F. Ortwine, S. G. Ross-Kesten, A. D. Sercel, W. R. Turner, L. M. Werbel, D. F. Worth, E. F. Elslager, W. R. Leopold, J. L. Shillis, Benzothiopyranoindazoles, a new class of chromophore modified anthracenedione anticancer agents. Synthesis and activity against murine leukemias. *J. Med. Chem.* 31 (1988) 1527-1539.
- [36] G. L. Ellman, D. Courtney, V. Andres, R. M. Featherstone, A new and rapid colorimetric determination of acetylcholinesterase activity. *Biochem. Pharmacol.* 7 (1961) 88-95.
- [37] S. Cellamare, A. Stefanachi, D. A. Stolfa, T. Basile, M. Catto, F. Campagna, E. Sotelo, P. Acquafredda, A. Carotti, Design, synthesis, and biological evaluation of glycine-based molecular tongs as inhibitors of A $\beta$ 1-40 aggregation in vitro. *Bioorg. Med. Chem.* 16 (2008) 4810-4822.
- [38] H. Sugimoto, H. Ogura, Y. Arai, Y. Limura, Y. Yamanishi, Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor. *Jpn. J. Pharmacol.* 89 (2002) 7-20.
- [39] K. Ono, Y. Yoshiike, A. Takashima, K. Hasegawa, H. Naiki, M. Yamada, Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease. *J. Neurochem.* 87 (2003) 172-181.

- [40] M. Catto, L. Pisani, F. Leonetti, O. Nicolotti, P. Pesce, A. Stefanachi, S. Cellamare, A. Carotti, Design, synthesis and biological evaluation of coumarin alkylamines as potent and selective dual binding site inhibitors of acetylcholinesterase. *Bioorg. Med. Chem.* 2013, 2, 146–152.
- [41] M. Bartolini, C. Bertucci, V. Cavrini, V. Andrisano. beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. *Biochem Pharmacol.* 2003, 65, 407-416.
- [42] M. Convertino, R. Pellarin, M. Catto, A. Carotti, A. Caflisch, 9,10-Anthraquinone hinders  $\beta$ -aggregation: How does a small molecule interfere with A $\beta$ -peptide amyloid fibrillation? *Protein Sci.* 18 (2009) 792-800.
- [43] C. Brühlmann, A. Marston, K. Hostettmann, P.-A. Carrupt, B. Testa, Screening of Non-Alkaloidal Natural Compounds as Acetylcholinesterase Inhibitors. *Chem. & Biodiv.* 1 (2004) 819-829.
- [44] M. T. H. Khan, I. Orhan, F.S. Şenol, M. Kartal, B. Şener, M. Dvorská, K. Šmejkal, T. Šlapetová, Cholinesterase inhibitory activities of some flavonoid derivatives and chosen xanthone and their molecular docking studies. *Chemico-Biol. Interact.* 181 (2009) 383-389.
- [45] A. Rampa, A. Bisi, P. Valenti, M. Recanatini, A. Cavalli, V. Andrisano, V. Cavrini, L. Fin, A. Burianni, P. Giusti, Acetylcholinesterase inhibitors: Synthesis and structure-activity relationships of  $\omega$ -[N-methyl-N-(3-alkylcarbamoyloxyphenyl)methyl]aminoalkoxyheteroaryl derivatives. *J. Med. Chem.* 41 (1998) 3976-3986.
- [46] L. Piazzi, F. Belluti, A. Bisi, S. Gobbi, S. Rizzo, M. Bartolini, V. Andrisano, M. Recanatini, A. Rampa, Cholinesterase inhibitors. SAR and enzyme inhibitory activity of 3-[ $\omega$ -(benzylmethylamino)alkoxy]xanthen-9-ones. *Bioorg. Med. Chem.* 15 (2007) 575-585.
- [47] S. Rizzo, A. Cavalli, L. Ceccarini, M. Bartolini, F. Belluti, A. Bisi, V. Andrisano, M. Recanatini, A. Rampa, Structure-activity relationships and binding mode in the human acetylcholinesterase active site of pseudo-irreversible inhibitors related to xanthostigmine. *ChemMedChem* 4 (2009) 670-679.
- [48] A. T. Petkova, Y. Ishii, J. J. Balbach, O. N. Antzutkin, R. D. Leapman, F. Delaglio, R. Tycko, A structural model for Alzheimer's  $\beta$ -amyloid fibrils based on experimental constraints from solid state NMR. *Proc. Natl. Acad. Sci. USA* 99 (2002) 16742-16747.
- [49] F. Aruga, K. Uto, T. Fujimara, H. Kimura, T. Koike, K. Ogura, F. Sagami, Acute toxicity study of donepezil hydrochloride in mice. *Yakuri to Chiryō* 26 (1998) Suppl. 6, S1163-S1168; *Chem. Abstr.* 130 (1999) 134058m.
- [50] S. S. Umarova, U. B. Zakirov, I. K. Kamilov, Comparative evaluation of the pharmacological action of quaternary galanthamine derivatives. *Farmakologiya Alkaloidov, Akad. Nauk Uzb. SSR, Inst. Khim. Rast Veshchestv.* 2 (1965), 258-263; *Chem. Abstr.* 66 (1967) 53993v.

**Table 1. Inhibitory activities of lucanthone and compounds 1-36<sup>a</sup>**

Compound	eeAChE		hsBChE		A $\beta$ aggregation	
	% at 10 $\mu$ M	IC <sub>50</sub> ( $\mu$ M)	% at 10 $\mu$ M	IC <sub>50</sub> ( $\mu$ M)	% at 100 $\mu$ M	IC <sub>50</sub> ( $\mu$ M)
Lucanthone		5.7		0.72		24
<b>1</b>	34			6.1		28
<b>2</b>		5.2		0.46		0.84
<b>3</b>		8.3		0.93		4.3
<b>4</b>		0.18		0.088		4.3
<b>5</b>		0.82		0.57	46	
<b>6</b>		5.8		1.9		5.9
<b>7</b>		4.9		0.72		2.9
<b>8</b>		7.6		0.94		4.3
<b>9</b>		4.5		0.43		2.5
<b>10</b>		3.3		0.30		20
<b>11</b>		1.1		0.98		13
<b>12</b>		0.77		0.60		11
<b>13</b>		2.0		0.15		9.1
<b>14</b>		0.12		2.0		7.9
<b>15</b>		0.5		0.88		17
<b>16</b>		4.8		0.41		14
<b>17</b>		2.0		0.48		1.3
<b>18</b>		1.9		0.15		13
<b>19</b>		4.8		0.45		21
<b>20</b>		2.7		2.4		48
<b>21</b>		0.14		0.37		13
<b>22</b>		9.4		0.75	55	
<b>23</b>		5.8	36		27	
<b>24</b>		0.46	25		35	
<b>25</b>		0.16		7.5	9	
<b>26</b>		1.5	47		0	
<b>27</b>		0.93		9.8	44	
<b>28</b>		0.011		12	43	
<b>29</b>		0.41		4.1		61
<b>30</b>		2.5	18		47	
<b>31</b>		1.3		2.9		6.4
<b>32</b>		1.9		1.6		31
<b>33</b>		0.84		1.3		9.7
<b>34</b>		0.84		1.1		8.3
<b>35</b>		1.9		1.6	66	
<b>36</b>		3.8		3.4		61
Donepezil		0.020		1.9	0	
Quercetin	9		0			0.82

<sup>a</sup> values are means of two/three independent experiments; SEM always < 10%.

**Table 2. Inhibitory activities on hAChE<sup>a</sup>**

Compound	IC <sub>50</sub> (μM)
<b>2</b>	3.5 ± 0.1
<b>28</b>	0.040 ± 0.006
Donepezil	0.019 ± 0.005

<sup>a</sup> values are means of two independent experiments ± SEM.